Sign In
Buy CAR
$173.86
+1.48 (+0.86%)
At Close: Jun 03, 2026
Canadian Apartment REIT: Bull Case Remains Firmly Intact
10:43pm, Monday, 15'th Jul 2024
After 18 months on the sidelines, we gave CAPREIT a buy on our last evaluation. The stock has outperformed the REIT Index ETF by a 2:1 margin since then. We tell you why we are staying with a Buy rati
Avis Budget Group to Announce Second Quarter 2024 Results on August 5th
04:00pm, Thursday, 11'th Jul 2024
PARSIPPANY, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its second quarter 2024 results after the market close on Monday, Augu
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
09:31am, Monday, 08'th Jul 2024
LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailb
Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy
01:39pm, Wednesday, 03'rd Jul 2024
Atara Biotherapeutics is a biotech company developing allogeneic EBV T cells for oncology and autoimmune indications, with a world-first allogeneic CAR-T approval in Europe and nearing FDA approval. A
Cartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T Drugs
10:55am, Tuesday, 02'nd Jul 2024
Cartesian Therapeutics reported a "watershed moment" for its autoimmune-disease drug on Tuesday, but the biotech stock plunged.
SOUTH SAN FRANCISCO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies usin
Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinoma Nomination triggers a $2 million milestone payment to Carisma PHILADELPHIA , June 27, 202
SOUTH SAN FRANCISCO, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies f
Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial
08:45am, Monday, 24'th Jun 2024
This patient is expected to be the final patient in the second dosage cohort of the trial SAN JOSE, Calif. , June 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: A
This IND clearance expands the use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-8 clinical trial targeting a devastating neuroimmunological autoimmune disease KYV-101 is a fully human a
SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo., June 20, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of alloge
Crown88, Asia's Premier Gaming Provider Collaborates with Taiwanese Influencer Avis in Expansion Endeavors
06:00am, Thursday, 20'th Jun 2024
Singapore, Singapore--(Newsfile Corp. - June 20, 2024) - Crown88, a pioneer in the Online Gaming Industry since its inception in 2010, has been steadily broadening its reputable services across multip
Dublin, June 17, 2024 (GLOBE NEWSWIRE) -- The "Avis Budget Group (Avis) - Digital Transformation Strategies" company profile has been added to ResearchAndMarkets.com's offering. The report provides co
Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
04:01pm, Friday, 14'th Jun 2024
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T
